K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy

References

• The GLOBOCAN Project. . http://globocan.iarc.fr/
   Google Scholar
• Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366:643 - 54; http://dx.doi.org/10.1038/366643a0; PMID: 8259209
   PubMed Web of Science ®Google Scholar
• Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263 - 93; http://dx.doi.org/10.1038/sj.leu.2402945; PMID: 12835716
   PubMed Web of Science ®Google Scholar
• Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?. Cell Cycle 2009; 8:1168 - 75; http://dx.doi.org/10.4161/cc.8.8.8147; PMID: 19282669
   PubMed Web of Science ®Google Scholar
• Czajkowski R, Placek W, Tadrowski T, et al. Geny BRAF, NRAS, HRAS w liniach komórkowych czerniaka ludzkiego. Przegl Dermatol 2009; 96:265 - 70
   Google Scholar
• Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33:392 - 406; http://dx.doi.org/10.1053/j.seminoncol.2006.04.002; PMID: 16890795
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11 - 22; http://dx.doi.org/10.1038/nrc969; PMID: 12509763
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682 - 9; PMID: 2547513
   PubMed Web of Science ®Google Scholar
• Nishimura S, Sekiya T. Human cancer and cellular oncogenes. Biochem J 1987; 243:313 - 27; PMID: 3307760
   PubMed Web of Science ®Google Scholar
• Edkins S, O’Meara S, Parker A, Stevens C, Reis M, Jones S, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5:928 - 32; http://dx.doi.org/10.4161/cbt.5.8.3251; PMID: 16969076
   PubMed Web of Science ®Google Scholar
• Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984; 312:71 - 5; http://dx.doi.org/10.1038/312071a0; PMID: 6092966
   PubMed Web of Science ®Google Scholar
• Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007; 34:546 - 54; http://dx.doi.org/10.1053/j.seminoncol.2007.09.011; PMID: 18083378
   PubMed Web of Science ®Google Scholar
• Nandan MO, Yang VW. An update on the biology of RAS/RAF mutations in colorectal cancer. Curr Colorectal Cancer Rep 2011; 7:113 - 20; http://dx.doi.org/10.1007/s11888-011-0086-1; PMID: 21625338
   PubMedGoogle Scholar
• Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009; 8:731 - 5; http://dx.doi.org/10.4161/cc.8.5.7848; PMID: 19221485
   PubMed Web of Science ®Google Scholar
• Khanafshar E, Lloyd RV. The spectrum of papillary thyroid carcinoma variants. Adv Anat Pathol 2011; 18:90 - 7; http://dx.doi.org/10.1097/PAP.0b013e3182026da6; PMID: 21169742
   PubMedGoogle Scholar
• Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al, Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855 - 67; http://dx.doi.org/10.1016/S0092-8674(04)00215-6; PMID: 15035987
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949 - 54; http://dx.doi.org/10.1038/nature00766; PMID: 12068308
   PubMed Web of Science ®Google Scholar
• Cervera P, Fléjou JF. Changing pathology with changing drugs: tumors of the gastrointestinal tract. Pathobiology 2011; 78:76 - 89; http://dx.doi.org/10.1159/000315535; PMID: 21677471
   PubMed Web of Science ®Google Scholar
• Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009; 9:179; http://dx.doi.org/10.1186/1471-2407-9-179; PMID: 19515263
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16:790 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446; PMID: 20103678
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753 - 62; http://dx.doi.org/10.1016/S1470-2045(10)70130-3; PMID: 20619739
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924 - 30; http://dx.doi.org/10.1200/JCO.2008.21.6796; PMID: 19884556
   PubMed Web of Science ®Google Scholar
• Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931 - 7; http://dx.doi.org/10.1200/JCO.2009.22.4295; PMID: 19884549
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rougier P, Köhne CH. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status. ECCO-ESMO 2009; Abstr.No: 6.077.
   Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040 - 8; http://dx.doi.org/10.1056/NEJMoa071834; PMID: 18003960
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757 - 65; http://dx.doi.org/10.1056/NEJMoa0804385; PMID: 18946061
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697 - 705; http://dx.doi.org/10.1200/JCO.2009.27.4860; PMID: 20921465
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; 26:823 - 33; http://dx.doi.org/10.1007/s00384-011-1149-0; PMID: 21286919
   PubMed Web of Science ®Google Scholar
• Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46:1997 - 2009; http://dx.doi.org/10.1016/j.ejca.2010.03.036; PMID: 20413299
   PubMed Web of Science ®Google Scholar
• Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21:2396 - 402; http://dx.doi.org/10.1093/annonc/mdq258; PMID: 20501503
   PubMed Web of Science ®Google Scholar
• Lagautrière F, Valvano L, Chaazl M, Benchimol D, Bernard JL, Bourgeon A, et al. [Prognostic factors in colorectal adenocarcinoma]. Ann Ital Chir 1998; 69:491 - 6, discussion 496-7; PMID: 9835125
   PubMedGoogle Scholar
• Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al, Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905 - 14; http://dx.doi.org/10.1056/NEJM200009283431302; PMID: 11006366
   PubMed Web of Science ®Google Scholar
• Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26:1443 - 51; http://dx.doi.org/10.1200/JCO.2007.14.0509; PMID: 18349394
   PubMed Web of Science ®Google Scholar
• Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 2009; 52:1359 - 66; http://dx.doi.org/10.1007/DCR.0b013e3181a7b7de; PMID: 19617745
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309 - 18, discussion 318-21; http://dx.doi.org/10.1097/00000658-199909000-00004; PMID: 10493478
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705 - 12; http://dx.doi.org/10.1200/JCO.2008.18.0786; PMID: 19001320
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706 - 13; http://dx.doi.org/10.1200/JCO.2009.27.6055; PMID: 20921462
   PubMed Web of Science ®Google Scholar
• Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nat Rev Clin Oncol 2009; 6:528 - 34; http://dx.doi.org/10.1038/nrclinonc.2009.106; PMID: 19597509
   PubMed Web of Science ®Google Scholar